A new blood-pressure treatment has come on the market that is of potential interest to hypertension patients whose blood pressure is not being adequately controlled with monotherapy. Last month, the US Food and Drug Administration (FDA) approved Novartis’ Valturna (aliskiren and valsartan), which combines in a single pill valsartan , the active ingredient in Diovan — the top-selling branded high blood pressure medicine — and aliskiren , the active ingredient in Tekturna — the only ap